Amneal beats Q2 estimates, raises FY guidance; FDA approves CREXONT for Parkinson's

Amneal Pharmaceuticals, Inc.

2024-Q2 EPS reported -$0.28 revenue$1,360,971,000

Q2 net revenue $702M (+17% YoY); GAAP net income $6M ($0.02 diluted EPS).
Adjusted EBITDA $162M (+11% YoY); adjusted diluted EPS $0.16 vs $0.19 prior year.
Raising full-year 2024 guidance on broad-based growth across all segments.
FDA approved CREXONT (carbidopa/levodopa) for Parkinson's disease; launch expected September 2024.
Specialty revenue +7%, Generics +14% (driven by biosimilars), AvKARE +33%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.